critical limb ischemia

[Pluristem Therapeutics, Inc.] Pluristem Therapeutics, Inc. announced that the independent Data Monitoring Committee (DMC) of its global pivotal Phase III study for the treatment of critical limb ischemia (CLI) issued its recommendation letter following the interim analysis.

[Scientific Reports] The authors evaluated the effects of the number of implanted bone-marrow mononuclear cells on clinical outcomes in atherosclerotic peripheral arterial disease patients with critical limb ischemia who underwent cell therapy.

[Stem Cells Translational Medicine] Investigators explored the therapeutic efficacy of human induced pluripotent stem cell (iPSC)‐derived endothelial cell and iPSC‐derived smooth muscle cell in peripheral artery disease model.

[Hypertension] Researchers discuss the recent advances in proangiogenic gene therapy for critical limb ischemia and DNA vaccine for hypertension.

[Nature Communications] QKI-7 is highly expressed in human coronary arterial endothelial cells from diabetic donors, and on blood vessels from diabetic critical limb ischemia patients undergoing a lower-limb amputation.

[Proceedings of the National Academy of Sciences of the United States of America] Researchers demonstrated the biophysical and biochemical effects of preconditioning human mesenchymal stem cells for 96 hours on a three-dimensional extracellular matrix-based microgel platform.